$5.90
-0.15[-2.48%]
At close: Apr 25
$5.90
0[0.00%]
After Hours: 4:20PM EDT
Amneal Pharmaceuticals
(NASDAQ:AMRX)Latest News for Amneal Pharmaceuticals Stock (NASDAQ:AMRX)
Amneal Pharmaceuticals Stock (NASDAQ: AMRX)
Categories: All
Wednesday, April 24, 2024
- Amneal Pharmaceuticals shares are trading higher after the company announced FDA approval of OTC Naloxone Hydrochloride Nasal Spray for emergency treatment of an opiod overdose.Benzinga Newsdesk - 1 day ago
- Amneal Announces FDA Approval Of Over-The-Counter Naloxone Hydrochloride Nasal Spray For Emergency Treatment Of Opioid OverdoseBenzinga Newsdesk - 1 day ago
Tuesday, April 16, 2024
Friday, April 05, 2024
Monday, March 25, 2024
Thursday, March 21, 2024
Monday, March 04, 2024
Friday, March 01, 2024
- Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?Vandana Singh - Mar 1, 2024, 10:57AM
- Amneal Pharmaceuticals shares are trading higher after the company reported mixed Q4 earnings and issued 2024 guidance.Benzinga Newsdesk - Mar 1, 2024, 6:58AM
- Earnings Scheduled For March 1, 2024Benzinga Insights - Mar 1, 2024, 6:56AM
- Amneal Pharmaceuticals: Q4 Earnings InsightsBenzinga Insights - Mar 1, 2024, 6:40AM
- Amneal Expects Fiscal Year 2024 Adjusted EBITDA Of $580M-$620M, With Operating Cash Flow Of $260M-$300M And Capital Expenditures Of $60M-$70M Compared To $558M, $346M, and $43M In 2023, RespectivelyBenzinga Newsdesk - Mar 1, 2024, 6:09AM
- Amneal Forecasts Fiscal Year 2024 Revenues Of $2.55B-$2.65B Versus Consensus Of $2.58B And Adjusted EPS Of $$0.53-$0.63 Versus Consensus Of $0.59Benzinga Newsdesk - Mar 1, 2024, 6:06AM
- Amneal Pharmaceuticals Q4 Adjusted EPS $0.14 Beats $0.09 Estimate, Sales $616.98M Miss $634.23M EstimateBenzinga Newsdesk - Mar 1, 2024, 6:02AM
Thursday, February 29, 2024
Tuesday, February 27, 2024
Thursday, February 08, 2024
Monday, January 29, 2024
Wednesday, January 10, 2024
Friday, January 05, 2024
Wednesday, November 08, 2023
Tuesday, November 07, 2023
- Earnings Scheduled For November 7, 2023Benzinga Insights - Nov 7, 2023, 6:34AM
- Amneal Affirms 2023 Net Revenue Outlook Of $2.37B-$2.42B, Adj. EPS Of $0.51-$0.58Benzinga Newsdesk - Nov 7, 2023, 6:05AM
- Amneal Pharmaceuticals Q3 Adj EPS $0.19 Beats $0.13 Estimate, Sales $620.04M Beat $595.27M EstimateBenzinga Newsdesk - Nov 7, 2023, 6:02AM
Tuesday, October 24, 2023
- Why Asbury Automotive Group Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Oct 24, 2023, 2:12PM
- Amneal Pharmaceuticals shares are trading higher after the company said it sees preliminary Q3 net revenue results above estimates.Benzinga Newsdesk - Oct 24, 2023, 1:39PM
- General Electric, Verizon, Cleveland-Cliffs And Other Big Stocks Moving Higher On TuesdayLisa Levin - Oct 24, 2023, 11:40AM
Monday, October 23, 2023
Thursday, October 12, 2023
Friday, October 06, 2023
Wednesday, September 06, 2023
- Amneal Receives U.S. FDA Approval For Calcium Gluconate Injection; Key Injectable Currently On The U.S. FDA Shortage List; Received Competitive Generic Therapy Approval DesignationHappy Mohamed - Sep 6, 2023, 4:00PM
- Analyst Ratings for Amneal PharmaceuticalsBenzinga Insights - Sep 6, 2023, 1:00PM
- Truist Securities Reiterates Buy on Amneal Pharmaceuticals, Maintains $6 Price TargetBenzinga Newsdesk - Sep 6, 2023, 12:06PM
- Amneal Pharmaceuticals Received Its First Product Approval In China. Sevelamer Carbonate Was Approved And Is Expected To Launch Shortly. In Addition, The Company Expects To Launch Oseltamivir Phosphate In China This Year As Well, Upon ApprovalBenzinga Newsdesk - Sep 6, 2023, 8:05AM
- Amneal Pharmaceuticals Received Abbreviated New Drug Application Approval From The FDA For Lisdexamfetamine Dimesylate Capsules, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, And 70 mgBenzinga Newsdesk - Sep 6, 2023, 8:04AM
Wednesday, August 16, 2023
Monday, August 07, 2023
- Piper Sandler Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $5Benzinga Newsdesk - Aug 7, 2023, 2:01PM
- Amneal Pharmaceuticals shares are trading higher after Truist Securities and Barclays raised their respective price targets on the stock.Benzinga Newsdesk - Aug 7, 2023, 1:19PM
- Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $6Benzinga Newsdesk - Aug 7, 2023, 10:21AM
- Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $5Benzinga Newsdesk - Aug 7, 2023, 9:07AM